Mesenchymal stromal cells (MSCs) possess broad immunomodulatory capacities that are currently investigated for potential clinical application in treating autoimmune disorders. Third-party MSCs suppress alloantigen-induced proliferation of peripheral blood mononuclear cells providing the rationale for clinical use in graft-versus-host disease (GvHD). We confirmed that MSCs strongly inhibited proliferation of CD8+ T cells in a mixed lymphocyte reaction. However, MSCs also suppressed proliferation of T cells specifically recognizing cytomegalovirus (CMV) and influenza virus. Inhibition was dose dependent, but independent of the culture medium. MSCs inhibited proliferation of specific CD8+ T cells and the release of IFN-γ by specific CD8+ T cells for immunodominant HLA-A2- and HLA-B7-restricted antigen epitopes derived from CMV phosphoprotein 65 and influenza matrix protein. This is in contrast to a recently reported scenario where MSCs exert differential effects on alloantigen and virus-specific T cells potentially having an impact on surveillance and prophylaxis of patients treated by MSCs.
CITATION STYLE
Malcherek, G., Jin, N., Hückelhoven, A. G., Mani, J., Wang, L., Gern, U., … Schmitt, M. (2014). Mesenchymal stromal cells inhibit proliferation of virus-specific CD8+ T cells. Leukemia, 28(12), 2388–2394. https://doi.org/10.1038/leu.2014.273
Mendeley helps you to discover research relevant for your work.